Articles tagged with Ovarian Tumors
In a breakthrough study, researchers found that dendritic cells, a type of immune cell, can be co-opted by tumors to promote angiogenesis and tumor growth. The study suggests a new approach to fighting solid tumors by targeting the interaction between angiogenesis and the immune response.
Researchers found that ovarian cancer tumors lack response to antiestrogens due to decreased ER beta expression, which can lead to increased cell proliferation and apoptosis. The reintroduction of ER beta in cancer cells induced apoptosis, suggesting its regulatory functions in controlling ovarian cancer growth and motility.
Researchers at Thomas Jefferson University have made significant progress in developing a new vaccine against malignant melanoma, a potentially deadly skin cancer. The vaccine showed promise in a phase I-II study, with 8 of 10 patients developing positive responses to their own tumor cells that were chemically modified.
Researchers examined 45 primary ovarian carcinoma samples and found that 40% had decreased or complete loss of Rb2 protein expression. The study suggests Rb2's role in ovarian carcinogenesis and potential clinical applications for detecting and treating cancer.
Researchers found that galectin-1, a molecule present in various tumor types, negatively impacts T cell survival and contributes to tumor progression. Inhibition of galectin-1 significantly reduces tumor formation in mice, highlighting its potential as a molecular target for cancer immunotherapy.
A recent study has confirmed that women with BRCA breast cancer who undergo conservation surgery and radiotherapy have a lower risk of recurrence compared to those without genetic mutations. The only factor associated with a higher risk of recurrence is young age, according to the researchers.
A novel gene therapy delivery system using stem cells has been developed to target and attack tumors, regardless of their location in the body. The system, which uses human mesenchymal progenitor cells, has shown promising results in tests with mice with various types of cancer, including ovarian, brain, breast, melanoma, and leukemia.
A new biomarker for ovarian and uterine carcinomas has been identified, associated with poor clinical outcome. L1 glycoprotein was found in 46 of 58 ovarian cancers and 20 of 72 uterine cancers, indicating a bad prognostic factor for patient survival.
Researchers found that 68% of invasive low-grade ovarian tumors and 61% of precancerous lesions carried one of the three common mutations in BRAF or KRAS. Blocking KRAS-BRAF signaling may provide more effective therapy for these cancers, which generally do not respond well to conventional chemotherapy.
Two new studies published in the Journal of the National Cancer Institute identified key risk factors for classical Kaposi's sarcoma and found that smoking may decrease the risk of this disease. Meanwhile, research on leptin suggests it controls breast cancer cell proliferation. Additionally, a potential screening tool for ovarian canc...
Research highlights increased cervical cancer risk in smokers, while ovarian tumors with BRCA2 mutations also commonly have BRCA1 mutations. A potential therapeutic approach for eliminating malignant urothelial cells is also explored through CD40 ligation.
Researchers developed a gene therapy combining radiation therapy and cisplatin to target tumor cells, resulting in significant regression with no additional toxicity. The treatment uses a modified cold virus to insert the TNF gene into tumor cells, enhancing anti-cancer effects.
Researchers found that genistein in dietary supplements negates the tumor-fighting effects of tamoxifen for women with estrogen-dependent breast cancer. High doses of isoflavones, commonly used in US supplements, can stimulate breast cancer growth.
Researchers at UC Davis have found that genes in one part of a plant can override the genetic program in a distant part, changing how it grows. They also developed a new method to permanently bind radioactivity to antibodies to deliver cancer treatment.
A new vaccine has shown promise in boosting immune responses against HER-2/neu protein in patients with breast and ovarian cancer. Researchers have identified a key protein fragment that can trigger an immune response, leading to sustained detectable immunity up to two years after vaccination.
Researchers found that combretastatin A-4 prodrug significantly enhances the effectiveness of standard chemotherapy agents in laboratory animals. Combining the drug with chemotherapy resulted in a 10 to 500 times increase in tumor cell death, compared to using chemotherapy alone.
A new ovarian tumor index helps physicians accurately diagnose ovarian tumors as either cancerous or benign. The index uses real-time ultrasound findings, patient age, and other characteristics to provide a valuable way for clinicians to plan further testing, surgery, or other clinical management.
The U-M research will systematically study the proteins made by tumor cells, genes that instruct them, and subtle differences among proteins from different types of tumors. The goal is to develop rapid-analysis technology to detect cancer early and predict treatment response.
Researchers at Yale University have successfully inserted a human cancer-suppressing gene into fruit flies, demonstrating a direct link between human and fly tumor suppressor genes. The study reveals that the insects can provide important new insights into human cancers.
Researchers at Rockefeller University have found evidence of naturally occurring tumor immunity in humans, where the immune system targets a specific protein called cdr2 to fight cancer. This discovery provides support for immunotherapy treatments and offers new insights into cancer biology.